Chimerix to Present at B. Riley Virtual Oncology Conference

Rhea-AI Summary

Chimerix (NASDAQ:CMRX) will have Mike Andriole, Chief Business and Financial Officer, present a corporate overview at the B. Riley Virtual Oncology Conference on January 27, 2022, at 3:00 p.m. ET. An audio webcast of the presentation will be accessible on the Investor Relations section of Chimerix's website for about 90 days following the event.

Chimerix is dedicated to developing medicines for deadly diseases, notably having received FDA approval for TEMBEXA for smallpox treatment. The company is also advancing ONC201 for recurrent glioma and DSTAT for acute myeloid leukemia.

DURHAM, N.C., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced Mike Andriole, Chief Business and Financial Officer, will present a corporate overview at the B. Riley Virtual Oncology Conference on Thursday, January 27, 2022 at 3:00 p.m. ET.

An audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix

Chimerix is a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. In June 2021, the U.S. Food and Drug Administration granted approval of TEMBEXA for the treatment of smallpox as a medical countermeasure. The Company has two other advanced clinical-stage development programs, ONC201 and dociparstat sodium (DSTAT). ONC201 is in development for recurrent H3 K27M-mutant glioma as its lead indication. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia.

CONTACT:
Investor Relations:        
Michelle LaSpaluto
919-972-7115
ir@chimerix.com

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

 

FAQ

When will Chimerix's corporate overview be presented at the B. Riley Virtual Oncology Conference?

Chimerix's corporate overview will be presented on January 27, 2022, at 3:00 p.m. ET.

Who is presenting for Chimerix at the B. Riley Virtual Oncology Conference?

Mike Andriole, Chief Business and Financial Officer, will present for Chimerix.

How can I access the audio webcast of Chimerix's presentation?

The audio webcast can be accessed on the Investor Relations section of Chimerix's website.

What is the duration for which the webcast will be archived?

The webcast will be archived for approximately 90 days.

What recent FDA approval did Chimerix receive?

Chimerix received FDA approval for TEMBEXA for the treatment of smallpox.

What other programs is Chimerix developing?

Chimerix is developing ONC201 for recurrent glioma and DSTAT for acute myeloid leukemia.